​Palmitoylethanolamide Chronic Pelvic Pain

Abstracts:

[Administration of micronized palmitoylethanolamide (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results].

​Palmitoylethanolamide Osteoarthritis

Studies/Abstracts:  Palmitoylethanolamide and Osteoarthritis

• Palmitoylethanolamide (PEA) improved function and reduced pain, stiffness, and anxiety without serious toxicity in a randomized controlled trial (RCT) of patients with knee osteoarthritis (KOA).

Why this matters

• PEA has the potential to be a natural, nontoxic, and targeted treatment option for KOA.

Study design

• RCT of 111 patients with mild to moderate knee osteoarthritis, receiving 300 mg PEA, 600 mg PEA, or placebo daily for 8 weeks.
• Function was assessed by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
• Funding: None disclosed.

Key results

• Efficacy at week 8, with each PEA dose compared with placebo:
  • Reduction in WOMAC total score: 300 mg, P=.037; 600 mg, P=.001.
  • Reduction in WOMAC pain subscore: 300 mg, P=.007; 600 mg, P<.001.>
  • Reduction in WOMAC stiffness subscore: 300 mg. P=.049; 600 mg, P=.001.
  • Reduction in WOMAC function subscore: 300 mg, NS; 600 mg, P=.003.
  • Reduction in anxiety on the Depression Anxiety Stress Scale: 300 mg, P=.042; 600 mg, P=.043.
• Safety at week 8, with each PEA dose compared with placebo:
  • No differences in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
  • No differences in numerous biochemical and hematological parameters.
  • No reports of serious toxicity.

Limitations

• No reporting of nonserious adverse events.
• Single-center study.”

https://www.univadis.co.uk/viewarticle/palmitoylethanolamide-shows-benefit-in-knee-osteoarthritis-664187

BMC Vet Res. 2017; 13: 229.

Published online 2017 Aug 2. doi: 10.1186/s12917-017-1151-z

PMCID: PMC5541643

PMID: 28768536

A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models

Domenico Britti,¹ Rosalia Crupi,² Daniela Impellizzeri,² Enrico Gugliandolo,² Roberta Fusco,² Carlo Schievano,³ Valeria Maria Morittu,¹ Maurizio Evangelista,⁴ Rosanna Di Paola,² and Salvatore Cuzzocrea^2,5

Author information Article notes Copyright and License information Disclaimer

This article has been cited by other articles in PMC.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541643/

Abstract

Background

Osteoarthritis (OA) is a common progressive joint disease in dogs and cats. The goal of OA treatment is to reduce inflammation, minimize pain, and maintain joint function. Currently, non-steroidal anti-inflammatory drugs (e.g., meloxicam) are the cornerstone of treatment for OA pain, but side effects with long-term use pose important challenges to veterinary practitioners when dealing with OA pain. Palmitoylethanolamide (PEA) is a naturally-occurring fatty acid amide, locally produced on demand by tissues in response to stress. PEA endogenous levels change during inflammatory and painful conditions, including OA, i.e., they are typically increased during acute conditions and decreased in chronic inflammation. Systemic treatment with PEA has anti-inflammatory and pain-relieving effects in several disorders, yet data are lacking in OA. Here we tested a new composite, i.e., PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA. Oral treatment with meloxicam was used as benchmark.

Conclusion

The present findings shed new light on some of the inflammatory and nociceptive pathways and mediators targeted by PEA-Q and confirm its anti-inflammatory and pain-relieving effects in rodent OA pain models. The translatability of these observations to canine and feline OA pain is currently under investigation.

Conclusions

PEA-Q is a novel co-ultramicronized formulation of PEA and quercetin whose effects were investigated in two pre-clinical models of OA pain in rats. Oral administration of PEA-Q decreased pain sensitivity, improved locomotor function, reduced inflammatory signs and mediators and lowered histological damage score. Although the underlying mechanism(s) of the observed effects are beyond the scope of our study, the particular cellular targets of PEA (e.g., mast cells and microglia) [19], redundancy of its receptors (direct and direct agonism on nuclear and membrane cannabinoid receptors) [14] and oxidative stress addressed by quercetin [22, 37] comprise targets that could be different from standard pharmacological tools (i.e., NSAIDs). Importantly, toxicological studies show that micronized and ultramicronized PEA is safe, the LD50 being greater than 2000 mg/kg [53]. Individually or in association with different antioxidant polyphenols, micronized and ultramicronized PEA has a long track record of use in human and veterinary patients, with good-to-excellent tolerability [14]. Moreover, prolonged use of PEA is not associated with the development of tolerance [43, 54]. There is an unmet need in veterinary medicine for the development of new agents to treat OA-associated pain which target alternative mechanisms distinct from currently approved drugs. The collective observations presented here propose that PEA-Q shows promise for multimodal pain management in canine and feline OA.”

Full Study:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541643/

 

DISCLAIMER:

The information provided on this page is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you have read here raises questions or concerns regarding your health.

No claims are made here about benefits of PEA in any medical condition, as PEA (not a prescription item) is governed by TGA in Australia.  Research is shown for readers education only.

​Palmitoylethanolamide Carpal Tunnel

Studies on the use of Palmitoylethanolamide (PEA) for Carpal Tunnel

•  This study suggests doses higher than 600mg per day are necessary.  Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study.  
  J Orthop Traumatol. 2017 Dec; 18(4): 451–455.  Jordi Faig-Martí, Adriana Martínez-Catassús

  Published online 2017 Mar 15. doi: 10.1007/s10195-017-0453-z
  The results of this study suggest that treatment of CTS with PEA at a dose of 600 mg/day is not associated with an improvement of any clinical and electrophysiological parameters. However, we observed an improvement in the FSS in the Boston Questionnaire after treatment with PEA. Together with the results of other studies, we conclude that further studies of PEA in CTS at higher doses are necessary.  Full article
• “Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome” Authors Hesselink J, Kopsky DReceived 25 July 2015

  Accepted for publication 17 September 2015

   Conclusion:

  “PEA has been tested in a variety of animal models for nerve compression and has been evaluated in eight different clinical trials in total, in 1,366 patients with nerve compression syndromes. Both the preclinical as well as the clinical results point in the same direction: PEA acts as a safe analgesic compound in nerve compression. Its safety and efficacy profile supports the clinical use of PEA in compression syndromes such as sciatic pain and carpal tunnel syndrome. PEA is easy to administer. The NNT of PEA for sciatic pain to reach 50% pain reduction is 1.5 and the number needed to harm is at least in the hundreds, but for the time being not calculable due to the absence of serious and troublesome side effects leading to dropouts in clinical trials. The risk–benefit balance of PEA therefore favors its inclusion in the therapeutic armamentarium of chronic pain. PEA can be administered both as a stand-alone analgesic as well as part of a multimodal therapy regime.”        [NNT ratio:  Number Needed to Treat:  The ideal NNT is 1, where everyone improves with treatment and no one improves with control. A higher NNT indicates that treatment is less effective. NNT is similar to number needed to harm (NNH), where NNT usually refers to a therapeutic intervention and NNH to a detrimental effect or risk factor.]

  Full Article

Here is a good summary article about PEA that talks about chronic pain conditions and it’s use.  https://www.fxmedicine.com.au/blog-post/pea-pain  Summary:

• “Used for its neuroprotective, anti-inflammatory and analgesic actions, PEA belongs to a new class of analgesic products.
• PEA has been evaluated in a number of placebo-controlled randomised clinical trials and has been found effective in various neuropathic pain states and inflammation, as well as in chronic pain.
• PEA has an excellent safety profile and is devoid of addiction potential. Drug interactions have not been documented and it may be used together with other analgesics or as a stand-alone therapy.

DISCLAIMER:

The information provided on this page is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you have read here raises questions or concerns regarding your health.

​Palmitoylethanolamide Neuropathy

Research on ​Palmitoylethanolamide (PEA) & Neuropathy

Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series

Extract:

”

PEA to protect against chemotherapy-induced painful polyneuropathy

Chemotherapy-induced neuropathic pain (patient 1) must be taken into account for both the associated disability and distress, but also to optimize the chemotherapy itself. Recently, the effect of PEA on pain and nerve functions in patients with chemotherapy-induced painful neuropathy was assessed.26 In brief, 20 patients undergoing thalidomide plus bortezomib treatment for multiple myeloma received 300 mg PEA twice daily for 2 months, starting after chemotherapy-induced neurotoxicity was established. Although no variable returned to normal, pain and all neurophysiological measures – assessing Aα, Aβ, and Aδ fibers – significantly improved. These results suggest a possible neuroprotective effect of PEA on myelinated nerve fibers. Importantly, concomitant PEA treatment allowed the maintenance of chemotherapeutic dose without further deterioration of nerve functions. The ability to continue chemotherapy in patients suffering from neuropathic pain, instead of stopping or reducing therapy, would clearly impact positively on survival rates also. A multicenter double-blind study evaluating the efficacy and safety of PEA in chemotherapy-induced neuropathic pain is currently in progress.

Conclusion

PEA represents a promising addition to our therapeutic armamentarium for neuropathic pain, with potential for good tolerability and a low propensity for side effects.

Full Article:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500919/

Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients

​Palmitoylethanolamide MS

​Palmitoylethanolamide Dental Pain

Studies Related to ​Palmitoylethanolamide and Dental Pain

”

Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy

Linda Gabrielsson, ¹ Sofia Mattsson, ¹ and Christopher J. Fowler ¹

Abstract

Palmitoylethanolamide (PEA) has been suggested to have useful analgesic properties and to be devoid of unwanted effects. Here, we have examined critically this contention, and discussed available data concerning the pharmacokinetics of PEA and its formulation. Sixteen clinical trials, six case reports/pilot studies and a meta‐analysis of PEA as an analgesic have been published in the literature. For treatment times up to 49 days, the current clinical data argue against serious adverse drug reactions (ADRs) at an incidence of 1/200 or greater. For treatment lasting more than 60 days, the number of patients is insufficient to rule out a frequency of ADRs of less than 1/100. The six published randomized clinical trials are of variable quality. Presentation of data without information on data spread and nonreporting of data at times other than the final measurement were among issues that were identified. Further, there are no head‐to‐head clinical comparisons of unmicronized vs. micronized formulations of PEA, and so evidence for superiority of one formulation over the other is currently lacking. Nevertheless, the available clinical data support the contention that PEA has analgesic actions and motivate further study of this compound, particularly with respect to head‐to‐head comparisons of unmicronized vs. micronized formulations of PEA and comparisons with currently recommended treatments.

DISCLAIMER:

The information provided on this page is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you have read here raises questions or concerns regarding your health.

No claims are made here about benefits of PEA in any medical condition, as PEA (a supplement that is not a prescription item) is governed by TGA in Australia.  Research is shown for readers education only.

​Palmitoylethanolamide Infection – Influenza and Common Cold

Palmitolyethanolamide (PEA) Shown To Be Effective In Reducing Influenza & Common Cold

It is not well known that over the past 25 years, PEA (Palmitoylethanolamide) has been tested as a therapy for both influenza and the common cold.  In fact, as early as 1939, food supplements (dried egg yolks fed to poor children in New York which containing high PEA) reduced rheumatic fever and streptococcal infections.  

This progressed over several decades leading to research in 1974 (Masek et al) that showed a 52% reduction in influenza in a trial with 1344 subjects.  People taking the palmitoylethanolamide had fewer episodes of fever, sore throat and headache than the placebo groups.  The number of sickness days was reduced in the PEA group.

To confirm these results – it was decided to test it on the military.

Soldiers that housed together were selected, and over 2 years from 1973 to 1975, new trials were conducted. 

The group taking the supplement had approximately one third the infection rate of the placebo group.

What else don’t you know about supplements?

Read more about palmitoylethanolamide at:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771453/

​Palmitoylethanolamide Fibromyalgia

​Palmitoylethanolamide for Asthma

Research Article in Frontiers in Pharmacology Shows That PEA Supplementation Reduces Airway Sensitivity Symptoms in Mice

You can create asthma symptoms in mice by a process called “allergen sensitization”.  This is related to the role of mast cells in asthma.

PEA appears to be a “down-regulator” of mast cell activity in the airways.  The first part of this study confirmed that PEA levels were LOWER in mice with created asthma symptoms (allergic symptoms in the lung tissue).  This fits into the model where cells with a lowered local level of PEA are more likely to be more easily inflamed or sensitive.  (Chronic pain and inflammation lead to REDUCED PEA levels in the cells.)

Simply put – this means that giving the mice asthma in this way, caused PEA levels in the cells to drop.

When the mice were supplemented with PEA (palmitoylethanolamide) at 10mg/kg 15 MINUTES before exposure to the allergen – this PREVENTED BRONCHIAL HYPERACTIVITY.

This supplementation also avoided pulmonary inflammation and allergen-induced cell recruitment (ie stopped the allergic cascade).

This has HUGE implications for allergy based sensitivity and corresponding asthma symptoms.  The mice developed lower PEA levels when exposed to the allergen, and when supplemented with PEA DID NOT DEVELOP THE ALLERGY AND SENSITIZATION.

​Palmitoylethanolamide Eczema